

Semaglutide and Tirzepatide for Obesity

Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- Black Women's Health Imperative
- Centene Corporation
- CVS Health
- Eli Lilly & Company
- Harold Bays, MD, Medical Director & President, Louisville Metabolic and Atherosclerosis Research Center
- Merck
- Novo Nordisk
- Obesity Action Coalition
- Obesity Medicine Association
- Prime Therapeutics
- The Obesity Society

We engaged with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having engaged with ICER:

- **Caroline Apovian, MD**, Co-Director, Center for Weight Management and Wellness, Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School
- **Melanie Jay, MD**, Professor of Medicine; Professor of Population Health, NYU Grossman School of Medicine
- **Katherine H. Saunders, MD, DABOM**, Co-Founder, FlyteHealth, Clinical Assistant Professor of Medicine, Weill Cornell Medicine

- **Gitanjali Srivastava, MD, FACP, FAAP**, Professor of Medicine, Pediatrics and Surgery, Medical Director, Obesity Medicine, Vanderbilt Health
- **Diana Thiara, MD**, Assistant Clinical Professor of Medicine, Medical Director, Weight Management Program, UCSF Health
- **Alexa M Triot, MD**, Assistant Medical Director, Healthcare Associates, Clinical Director of HCA Embedded Primary Care Weight Management Programs, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).